You are here

valrox

FDA delays review of BioMarin's hemophilia gene therapy after data update

Endpoints

Tue, 03/7/23 - 11:16 am

BioMarin nets conditional approval for valrox in Europe, marking the first hemophilia gene therapy

Endpoints

Thu, 08/25/22 - 10:59 am

BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts

Fierce Biotech

Mon, 01/10/22 - 11:32 am

clinical trials

Is valrox dead?

EP Vantage

Thu, 08/20/20 - 11:09 am

FDA gets out its red pen again, rejecting BioMarin's gene therapy valrox amid durability worries

Fierce Biotech

Wed, 08/19/20 - 09:28 am

Go or no go? Valuable drugs set for FDA decisions

EP Vantage

Wed, 07/29/20 - 10:54 am

belantamab mafodotin

Gilead Sciences

10 Drugs Expected to Enter the Market This Year Could be Blockbusters, Analysis Says

BioSpace

Mon, 03/9/20 - 11:10 pm

Bristol-Myers Squibb

BioMarin's Novel Treatment Promises to Disrupt Competitors

Motley Fool

Wed, 02/26/20 - 10:45 am

FDA Gives BioMarin Pharmaceuticals' Hemophilia Gene Therapy Priority Review

Motley Fool

Thu, 02/20/20 - 11:41 pm

priority review

Drugmaker BioMarin Seeks New CFO Amid Coming Release Of Potentially Costliest Drug In The World

Forbes

Thu, 02/6/20 - 11:37 pm

BioMarin Considers $3 Million Price Tag for New Hemophilia Gene Therapy

Motley Fool

Thu, 01/16/20 - 11:27 pm

BioMarin talks down worries on gene therapy data differences

Biopharma Dive

Tue, 09/10/19 - 11:39 pm

BioMarin drops lower dose of its hemophilia gene therapy as it eyes submissions by year-end

Fierce Biotech

Fri, 08/2/19 - 10:37 am

valoctocogene roxaparvovec

How BioMarin May Revolutionize the Hemophilia Treatment Market

Motley Fool

Tue, 05/28/19 - 11:25 pm

Two drugs in the pipeline representing unique marketing challenges

Medical Marketing and Media

Tue, 06/5/18 - 10:37 pm

Boehringer Ingelheim

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head study

Endpoints

Tue, 05/22/18 - 09:58 am